Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Free Cash Flow (2016 - 2025)

Protalix BioTherapeutics has reported Free Cash Flow over the past 16 years, most recently at $2.9 million for Q4 2025.

  • Quarterly results put Free Cash Flow at $2.9 million for Q4 2025, down 36.96% from a year ago — trailing twelve months through Dec 2025 was -$12.4 million (down 246.82% YoY), and the annual figure for FY2025 was -$12.4 million, down 246.82%.
  • Free Cash Flow for Q4 2025 was $2.9 million at Protalix BioTherapeutics, up from -$4.2 million in the prior quarter.
  • Over the last five years, Free Cash Flow for PLX hit a ceiling of $6.2 million in Q2 2021 and a floor of -$10.2 million in Q1 2021.
  • Median Free Cash Flow over the past 5 years was -$3.7 million (2021), compared with a mean of -$2.1 million.
  • Biggest five-year swings in Free Cash Flow: plummeted 328.87% in 2022 and later surged 221.6% in 2024.
  • Protalix BioTherapeutics' Free Cash Flow stood at -$4.2 million in 2021, then surged by 32.28% to -$2.8 million in 2022, then skyrocketed by 218.45% to $3.3 million in 2023, then surged by 37.34% to $4.6 million in 2024, then tumbled by 36.96% to $2.9 million in 2025.
  • The last three reported values for Free Cash Flow were $2.9 million (Q4 2025), -$4.2 million (Q3 2025), and -$5.7 million (Q2 2025) per Business Quant data.